Osteoporosis
428 results
101 - 200
Strontium ranelate for preventing and treating postmenopausal osteoporosis
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis - Bisphosphonate therapy for children and adolescents with secondary osteoporosis
American College of Rheumatology guideline for preventing and treating steroid-induced osteoporosis- Zoledronic acid reduces fracture risk in osteoporosis, osteopenia with previous fracture
- Teriparatide questionably better than alendronate in treating steroid-induced osteoporosis
- Hormone replacement for osteoporosis in women with primary biliary cirrhosis: Cochrane systematic review
- Treatment for osteoporosis in people with beta‐thalassaemia
- Bisphosphonates for osteoporosis in people with cystic fibrosis
- Bisphosphonates for steroid‐induced osteoporosis
- ACR guideline for managing patients with glucocorticoid-induced osteoporosis
- Osteoporosis screening in older women: fewer hip fractures but no overall reduction in fractures
- Bisphosphonates for osteoporosis in primary biliary cirrhosis: Cochrane systematic review
- MORES risk estimation tool for male osteoporosis screening
- Romosozumab prevents clinical fracture slightly better than alendronate in women with osteoporosis and previous fracture
- Exercise for preventing and treating osteoporosis in postmenopausal women: Cochrane systematic review
- Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy
- Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D
- USPSTF 2025 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)
- USPSTF 2018 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)
- Rheumatoid arthritis
- Parathyroid hormone prevents recurrent fractures
- No need to monitor BMD after bisphosphonates started
- Falls of the elderly
- Alendronate therapy unnecessary for most women after 5 years
- Teriparatide for the prevention of fractures in postmenopausal women
- Vitamin D supplementation for improving bone mineral density in children
- Primary biliary cholangitis
- Polymyalgia rheumatica
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
- Professional interventions for general practitioners on the management of musculoskeletal conditions
- Giant cell (temporal) arteritis
- Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
- Myositis
- Long-term adverse effects of antineoplastic agents
- Problems of childhood or adolescence cancer survivors in adulthood
- Most women quickly stop taking bisphosphonates
- Vitamin D, at high doses, prevents fractures
- Exercise for improving outcomes after osteoporotic vertebral fracture
- Cushing's syndrome
- Zoledronic acid reduces asymptomatic fractures but not clinical ones in men
- Tibolone prevents osteoporotic fracture, increases stroke risk (LIFT)
- Denosumab reduces fracture risk better than placebo (FREEDOM)
- Bisphosphonates decrease vertebral fractures but not clinically important fractures in men
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
- Pharmacological glucocorticoid treatment
- Denosumab no better than bisphosphonates at preventing fracture, and the cost is much higher
- Oral bisphosphonate use not associated with increased risk of esophageal cancer
- Reduced all-cause mortality associated with post-fracture bisphosphonate treatment
- Chronic obstructive pulmonary disease (COPD)
- Interventions for improving the appropriate use of imaging in people with musculoskeletal conditions
- Using alternative statistical formats for presenting risks and risk reductions
- Vitamins